Oral GLP-1 pill CX11 shows up to 11.5% weight loss in phase 2 trial

Corxel Pharmaceuticals' once-daily oral GLP-1 candidate CX11 met primary endpoints in a U.S. phase 2 trial and produced up to 11.5% weight loss after 36 weeks.

The study enrolled 246 adults with obesity or overweight and at least one weight-related comorbidity, then randomized them 1:1:1:1:1 to CX11 120 mg, 160 mg, 200 mg slow titration, 200 mg fast titration, or placebo. CX11 is an investigational oral small-molecule GLP-1 receptor agonist aimed at cardiometabolic conditions including obesity, overweight and type 2 diabetes.

Phase 2 trials are built to show proof of concept, explore dosing and monitor side effects, not to settle long-term effectiveness or rare safety problems. Weight loss continued at a steady rate through the study.

Safety was another focus. The most common adverse events were gastrointestinal, with nausea reported in 33% to 34% of participants and vomiting in 12% to 16%, depending on dose cohort. Diarrhea ranged from 4% to 12% and constipation from 2% to 12%. Those events were mostly mild to moderate, with no severe cases of those gastrointestinal effects and no hepatic safety signal in the U.S. trial.

Corxel first enrolled a patient in the U.S. study on June 17, 2025, and announced positive topline results on June 23, 2026. The company plans to advance CX11 into pivotal global phase 3 studies, building on an earlier phase 2 program in China and a recent phase 3 result there by Vincentage Pharma Co., Ltd.

In August 2025, Eli Lilly and Company’s oral GLP-1 orforglipron produced 12.4% average weight loss at 72 weeks in a phase 3 obesity trial. On June 8, 2026, AstraZeneca’s elecoglipron produced 11.8% weight loss at 36 weeks in a phase 2b study and was moving to phase 3.

Novo Nordisk’s oral Wegovy pill was approved by the U.S. Food and Drug Administration in December 2025, making it the first oral GLP-1 medicine for obesity in the United States.